WCN26-7764 ECULIZUMAB FOR REFRACTORY IgA NEPHROPATHY: A SINGLE-CENTER RETROSPECTIVE SERIES

Read full text Summarise with VIRAT
Authors: Fenglei Si, Chen Tang, Jicheng Lv, Sufang Shi, Xujie Zhou, Lijun Liu, Hong Zhang
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in adults. Its pathogenesis involves immune complexes with aberrantly glycosylated IgA1, which drive complement activation; both alternative and lectin complement pathways contribute to disease progression, and terminal complement complex (C5b-9) deposition correlates with adverse renal outcomes. Eculizumab, a monoclonal antibody against complement component C5, inhibits C5 cleavage and C5b-9 formation to reduce complement-mediated glomerular injury, but clinical evidence for its use in IgAN remains limited.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Complement system in diseases Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106301–106301
Publication date
25 March 2026
Language
EN